![Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-5021600-150x150.jpg "Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37] 19")
Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic Patients
A study comparing Tirzepatide to Semaglutide in diabetic CABG patients found significant benefits for cerebrovascular and cardiovascular outcomes, reducing mortality and complications.
Beyond weight loss- tirzepatide as a dual GIP:GLP-1 receptor agonist for obstruc
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been FDA-approved for treating moderate-to-severe OSA in obese adults. It significantly reduces AHI and improves sleep quality.
Dysesthesia associated with GLP-1 agonist therapies- data-mining analysis
A study reveals that GLP-1 agonists like semaglutide are linked to significant signals for hyperesthesia, dysesthesia, and burning sensation. These reactions are dose-dependent and can recur upon rechallenge.
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Tirzepatide treatment for 12 weeks resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
GLP-1 Receptor Agonists and Colorectal Cancer Risk
GLP-1 receptor agonists colorectal cancer risk reduction is an emerging benefit supported by observational evidence. These agents may reduce colorectal cancer risk through improved insulin sensitivity and reduced inflammation. This adds to their known…
Expanding GLP-1 Weight Loss Access via Telehealth Platforms
Telehealth platform expansion is transforming access to GLP-1 weight loss therapies. This shift enables broader patient reach while maintaining clinical standards. Understanding telehealth prescribing is essential for effective weight management outcomes.
GLP-1 Tirzepatide Cardiovascular Outcomes Clinical Evidence
Tirzepatide cardiovascular risk reduction is supported by clinical evidence demonstrating benefits beyond glucose control. This dual GIP/GLP-1 receptor agonist reduces major adverse cardiovascular events in high-risk populations. These findings position…
GLP-1 Receptor Agonist Randomized Trial Evidence
This article reviews GLP-1 receptor agonist randomized trial data focusing on weight loss and metabolic improvements. Semaglutide and tirzepatide clinical trials provide key insights into efficacy and safety. Understanding this data helps clinicians…
Managing Weight Regain After GLP-1 Receptor Agonist Therapy
GLP-1 receptor agonist weight regain prevention is critical for managing patients after therapy discontinuation. Understanding weight rebound patterns helps clinicians guide treatment adherence and tapering strategies. This focus on prevention supports…
Tirzepatide Cardiovascular Safety: Clinical Trial Evidence
Tirzepatide cardiovascular safety clinical trial evidence supports its use in managing cardiometabolic risks. Clinical trials show favorable cardiovascular outcomes with tirzepatide. This evidence aids clinicians in therapy selection for patients with…